SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous - 2Iran plans new restrictions in overhaul of Strait of Hormuz rules
- 3Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- 4The 3 little words TV fans can't stop obsessing over
- 5The Force of Care: Living with Goal
- Different Film Classification: What's Your Go-To for Amusement
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Many European nations want Israel to cancel 19 new settlement plans
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Track down the Ideal Weight reduction Methodology for Your Way of life
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Sunken warship found off Danish coast after 225 years in ‘remarkable’ discovery
- Germany's Merz under fire in Brazil for his comments on Amazon host city of COP30
